Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL CITRATE AND DROPERIDOL versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL CITRATE AND DROPERIDOL versus WESTADONE.
FENTANYL CITRATE AND DROPERIDOL vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a mu-opioid receptor agonist, producing analgesia and sedation. Droperidol is a butyrophenone antipsychotic that blocks dopamine D2 receptors in the brain, causing tranquilization and antiemetic effects.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Fentanyl 50-100 mcg IV and droperidol 2.5-5 mg IV, administered slowly over 1-2 minutes, repeated every 60 minutes as needed for breakthrough pain or sedation.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Fentanyl: 3-4 hours (terminal elimination half-life); prolonged in elderly and hepatic impairment. Droperidol: 2.2-2.5 hours (terminal elimination half-life).
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Fentanyl: primarily renal (75% as metabolites, <10% unchanged), with about 9% excreted in feces. Droperidol: renal (75% as metabolites, <1% unchanged), about 22% in feces.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist